| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/21/2013 | WO2013037487A1 A particulate system for use in diminishing cell growth/inducing cell killing |
| 03/21/2013 | WO2013037479A1 Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid |
| 03/21/2013 | WO2013037396A1 Solution of polymer in api for a solid dosage form |
| 03/21/2013 | WO2013037207A1 N-(3-pyridine formoxyl)- 3,5-dimethyl-1- amantadine or its pharmaceutical salt for treating vascular dementia |
| 03/21/2013 | WO2013037019A1 Process for producing boron nitride nanotubes, boron nitride nanotube, use of the boron nitride nanotube, and method for transforming bacteria |
| 03/21/2013 | WO2013014654A3 Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis |
| 03/21/2013 | WO2013012954A3 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| 03/21/2013 | WO2013009701A3 Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| 03/21/2013 | WO2012163704A3 Inhalator and capsule for an inhalator |
| 03/21/2013 | WO2012162555A3 Heparin nanoclusters |
| 03/21/2013 | WO2012161520A3 Injectable liquid composition containing docetaxel |
| 03/21/2013 | WO2012157993A3 Inorganic composite powder coated with octyl methoxycinnamate, and ultraviolet blocking cosmetic composition using same |
| 03/21/2013 | WO2012157921A3 Composition for transdermal administration, containing rivastigmine or salt thereof |
| 03/21/2013 | WO2012149405A3 Tolerogenic synthetic nanocarriers for regulating innate immune responses |
| 03/21/2013 | WO2012147101A3 Pharmaceutical compositions of raltegravir, methods of preparation and use thereof |
| 03/21/2013 | WO2012138906A3 Topical skin care formulations comprising plant extracts |
| 03/21/2013 | WO2012135592A3 Theranostic imaging agents and methods of use |
| 03/21/2013 | WO2011124589A3 Method and device for forming vesicles, in particular using block copolymers |
| 03/21/2013 | US20130072884 Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| 03/21/2013 | US20130072854 Microbubble complexes and methods of use |
| 03/21/2013 | US20130072567 Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine |
| 03/21/2013 | US20130072529 Pharmaceutical composition comprising aleglitazar |
| 03/21/2013 | US20130072517 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 03/21/2013 | US20130072514 Sustained-Release Opioid Formulations and Methods of Use |
| 03/21/2013 | US20130072508 Solid pharmaceutical dosage form |
| 03/21/2013 | US20130072498 Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| 03/21/2013 | US20130072424 Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics |
| 03/21/2013 | US20130071484 Self-Assembled Toroidal-Spiral Particles and Manufacture and Uses Thereof |
| 03/21/2013 | US20130071483 VACCINE PRODUCED USING OPTIMIZED IMMOBILIZATION ANTIGEN cDNA OF CRYPTOCARYON IRRITANS AND PRODUCING METHOD AND USE THEREOF |
| 03/21/2013 | US20130071482 Block copolymer cross-linked nanoassemblies as modular delivery vehicles |
| 03/21/2013 | US20130071481 Coated particle and method for producing coated particle |
| 03/21/2013 | US20130071480 Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances |
| 03/21/2013 | US20130071479 Microspheres |
| 03/21/2013 | US20130071477 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| 03/21/2013 | US20130071476 Rapid Melt Controlled Release Taste-Masked Compositions |
| 03/21/2013 | US20130071475 Method For Producing An Oral Pharmaceutical Form With Immediate Disintegration And Active Ingredient Release |
| 03/21/2013 | US20130071474 COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES |
| 03/21/2013 | US20130071473 Composition and method for treating ulcers |
| 03/21/2013 | US20130071472 Fascile synthesis of biocompatible polymer capsule nanoparticles for drug encapsulation |
| 03/21/2013 | US20130071470 Fenugreek Seed Extract to Lower Blood Cholesterol |
| 03/21/2013 | US20130071469 Lipid-Based Compositions of Antiinfectives for Treating Pulmonary Infections and Methods of Use Thereof |
| 03/21/2013 | US20130071468 Lipid-Based Compositions of Antiinfectives for Treating Pulmonary Infections and Methods of Use Thereof |
| 03/21/2013 | US20130071467 Retinoid-liposomes for treating fibrosis |
| 03/21/2013 | US20130071466 Methods and compositions for treating gastric disorders |
| 03/21/2013 | US20130071463 Implants for postoperative pain |
| 03/21/2013 | US20130071462 Drug Delivery Systems and Applications |
| 03/21/2013 | US20130071458 Active agents and their oligomers and polymers |
| 03/21/2013 | US20130071457 Wound Healing Device |
| 03/21/2013 | US20130071452 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof |
| 03/21/2013 | US20130071448 Treatment of t-cell mediated diseases |
| 03/21/2013 | US20130071447 Methods for producing ecm-based biomaterials |
| 03/21/2013 | US20130071446 Infant nutrition for improving fatty acid composition of brain membranes |
| 03/21/2013 | US20130071445 Transluminal drug delivery methods and devices |
| 03/21/2013 | US20130071443 Glycosaminoglycans |
| 03/21/2013 | US20130071442 Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections |
| 03/21/2013 | US20130071441 Cell construct for cell transplantation and cell aggregate for cell transplantation |
| 03/21/2013 | US20130071440 Use of simple amino acids to form porous particles |
| 03/21/2013 | US20130071439 Methods and compositions for treating biofilms |
| 03/21/2013 | US20130071438 Compositions and methods for the treatment of hyperplasia |
| 03/21/2013 | US20130071338 Formulation comprising nicotine and a cation exchange resin |
| 03/21/2013 | US20130071337 Interomone Compositions and Their Use to Modify Behavior in Different Vertebrate Species |
| 03/21/2013 | US20130071329 Theranostic delivery systems with modified surfaces |
| 03/21/2013 | US20130071326 Universal cell-directed theranostics |
| 03/21/2013 | US20130071322 Medical treatment applications of swellable and deformable microspheres |
| 03/21/2013 | US20130071321 Delivery of agents to inflamed tissues using folate-targeted liposomes |
| 03/21/2013 | US20130071319 Compositions and Methods for Surface Abrasion with Frozen Particles |
| 03/21/2013 | US20130068218 Process for producing metered dose inhaler formulations |
| 03/21/2013 | DE112011101896T5 Reduzieren von Defekten in elektronischen Vorrichtungen Reducing defects in electronic devices |
| 03/21/2013 | DE102006032083B4 Verfahren zur Herstellung von Mikrokapseln A process for the preparation of microcapsules |
| 03/21/2013 | CA2848965A1 Bioresorbable drug delivery matrices based on cross-linked polysaccharides, dosage forms designed for delayed/controlled release |
| 03/21/2013 | CA2848785A1 A fast dissolving pharmaceutical composition |
| 03/21/2013 | CA2848764A1 Controlled dosing of clopidogrel with gastric acid inhibition therapies |
| 03/21/2013 | CA2848740A1 Amphiphilic cationic polymers for the delivery of therapeutic agents |
| 03/21/2013 | CA2848493A1 Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
| 03/21/2013 | CA2848219A1 Compositions of jasmonate compounds and methods of use |
| 03/21/2013 | CA2848156A1 Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid |
| 03/21/2013 | CA2847698A1 Nanoconjugates able to cross the blood-brain barrier |
| 03/21/2013 | CA2847613A1 Tamper resistant immediate release formulations |
| 03/21/2013 | CA2847611A1 Tamper resistant pharmaceutical formulations |
| 03/21/2013 | CA2846824A1 Pharmaceutical composition for inhalation |
| 03/21/2013 | CA2845712A1 Smarttm solid oral dosage forms |
| 03/21/2013 | CA2845673A1 Pharmaceutical nanoparticle compositions |
| 03/21/2013 | CA2844923A1 Aqueous compositions comprising arbekacin |
| 03/20/2013 | EP2570432A1 Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| 03/20/2013 | EP2570126A1 Use of melatonine for treating acute alcohol intoxication |
| 03/20/2013 | EP2570124A1 Oleuropein compositions for healing wounds and ulcers in elderly people and/or diabetics |
| 03/20/2013 | EP2570122A1 Composition for Enhancing Transdermal Absorption of A Drug and Patch Preparation |
| 03/20/2013 | EP2570121A1 Slow release tablet of elemene anti-tumor plant medicine |
| 03/20/2013 | EP2570120A1 Coated particle and method for producing coated particle |
| 03/20/2013 | EP2570118A1 Combinations of hyaluronic acid and a vitamin for inhibiting inflammation |
| 03/20/2013 | EP2570117A1 Pharmaceutical topical compositions |
| 03/20/2013 | EP2570116A1 Composition for enhancing transdermal absorption of a drug and patch preparation |
| 03/20/2013 | EP2570115A1 Composition for enhancing transdermal absorption of a drug and patch preparation |
| 03/20/2013 | EP2569267A1 Improved methods for preparing squalene |
| 03/20/2013 | EP2569004A2 Lactoferrin -based biomaterials for tissue regeneration and drug delivery |
| 03/20/2013 | EP2568997A2 Compositions and methods which modulate g-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis |
| 03/20/2013 | EP2568988A1 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
| 03/20/2013 | EP2568987A2 Tetracycline compositions |
| 03/20/2013 | EP2568980A1 Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
| 03/20/2013 | EP2568979A2 Ratiometric combinatorial drug delivery |